Zhenyu Xu Sells 7,393 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 7,393 shares of the firm’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81. Following the sale, the insider owned 614,887 shares in the company, valued at approximately $3,178,965.79. This trade represents a 1.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total value of $3,167.68.
• On Tuesday, April 14th, Zhenyu Xu sold 600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.97, for a total value of $2,982.00.
• On Monday, April 13th, Zhenyu Xu sold 4,414 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $21,010.64.
• On Friday, April 10th, Zhenyu Xu sold 3,706 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.68, for a total value of $17,344.08.
• On Thursday, April 9th, Zhenyu Xu sold 1,936 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,176.64.
• On Wednesday, April 8th, Zhenyu Xu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total value of $13,552.00.

SOPHiA GENETICS Trading Up 1.9%

Shares of SOPH traded up $0.10 during mid-day trading on Tuesday, reaching $5.44. The company’s stock had a trading volume of 284,563 shares, compared to its average volume of 187,273. SOPHiA GENETICS SA has a 52 week low of $2.92 and a 52 week high of $6.30. The stock has a market cap of $456.36 million, a PE ratio of -10.46 and a beta of 0.96. The company’s fifty day moving average price is $5.12 and its two-hundred day moving average price is $4.96. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The business had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SOPH. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently modified their holdings of the stock. Silverberg Bernstein Capital Management LLC raised its position in shares of SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after purchasing an additional 4,155 shares during the last quarter. Green Alpha Advisors LLC grew its position in SOPHiA GENETICS by 10.8% during the 4th quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock valued at $213,000 after purchasing an additional 4,444 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after purchasing an additional 6,205 shares in the last quarter. Principal Financial Group Inc. increased its stake in SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Finally, First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the first quarter worth about $50,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.